Conference Coverage
Conference Coverage
Popular liver supplements lack data supporting efficacy, study shows
“But our research revealed that strong scientific evidence supporting the efficacy of any of these supplements is currently lacking.”
Conference Coverage
Gut microbiome variations may be predictive of precancerous colonic lesions, CRC
“We really need to find new predictors of tumorigenesis. We already have some good predictors, mainly FIT, but these are not enough. These gut...
Latest News
More phase 3 data support use of nemolizumab for prurigo nodularis
"Now I hope you understand why we are so excited," said lead investigator Sonja Ständer, MD.
Latest News
Birch bark–derived treatment reduces daily dressings in patients with epidermolysis bullosa
Despite being approved in Europe, Oleogel-S10 has not yet been approved to treat EB in the United States.
Latest News
AI flagged skin cancer with near-perfect accuracy, in UK study
The researchers tested the AI by integrating it into a clinical diagnosis process - anticipating a future in which AI helps doctors catch skin...
Conference Coverage
Beyond semaglutide, a coming pipeline of new antiobesity meds
With the two highest doses of retatrutide, 100% of participants lost ≥ 5% of weight. “I’m not sure how many other times I will ever be able to say...
Conference Coverage
Race-specific lung-function values may skew IPF testing
Race-specific equations may falsely inflate percent-predicted pulmonary function values in non-White patients, investigators caution.
Latest News
Novel hydrogel holds promise for skin regeneration
The first clinical trials for treating complex diabetic wounds are planned for early 2024.
Latest News
Tech encourages HIV prevention among women
“Mobile technologies, in particular, offer a nimble, customizable, and accessible way to reach this target population and increase awareness of...
Conference Coverage
SGLT2 inhibitors in type 2 diabetes linked to lower risk of developing GI cancers
The study is notable for including people with ulcerative colitis and Crohn’s disease and for evaluating every GI cancer.
Conference Coverage
IBD biologics, other therapies cleared of causing major adverse cardiovascular events
Biologics infliximab, adalimumab, golimumab, certolizumab, vedolizumab, natalizumab, and ustekinumab not only did not increase risk, but they...